Developing and validating SIM-2: the first therapeutic vaccine for Genital Herpes

Purpose and goal:

The HERVAX project aims to develop a new genital herpes (HSV-2) vaccine, for clinical trials. SIM-2 uses Simplexia´s patented technology to develop the gG2-EXCT4 antigen that will elicit an HSV-2-specific immune response, stopping disease progression and transmissibility of the virus. This will be the first therapeutic vaccine against HSV-2.

Expected results and effects: A candidate vaccine against genital herpes caused av Herpes simplex virus-2. Approach and implementation: Analytical Method Development Microparticle and microneedle development and screening Adjuvant screening with VFI candidate Analytical Method Development gG-2 EXCT4 microspheres

Dosing strategy identified using Mouse Challenge Model for HSV-2 Preclinical human in vitro efficacy studies